Amgen’s Growth Story Relies Mainly On Continuing Plot Lines

Forecasts Mid-Single-Digit Revenue CAGR Through 2030

 
• By Mandy Jackson
  
Top view of vintage typewriter with books and copy space
Amgen is writing a growth story built on Repatha, Otezla, biosimilars and new launches • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip